|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 113.84 CHF | -0.18% |
|
+4.92% | +3.87% |
| 06:20pm | Novartis AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:00 AM | |
| 05:56pm | Novartis eyes more bolt-on acquisitions, CEO says | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 6.08 | 6.18 | 6.45 | 7.27 | 10.09 | |||||
Return on Total Capital | 8.48 | 8.28 | 8.63 | 9.84 | 13.72 | |||||
Return On Equity % | 14.38 | 38.59 | 10.93 | 16.15 | 26.28 | |||||
Return on Common Equity | 14.4 | 38.66 | 10.95 | 16.16 | 26.33 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 71.14 | 70.81 | 70.9 | 74.24 | 75.22 | |||||
SG&A Margin | 28.24 | 28.02 | 27.38 | 26.77 | 24.29 | |||||
EBITDA Margin % | 34.89 | 33.92 | 34.74 | 37.54 | 39.95 | |||||
EBITA Margin % | 31.36 | 31.63 | 32.49 | 35.58 | 38.24 | |||||
EBIT Margin % | 24.42 | 24.25 | 24.81 | 27.09 | 31.55 | |||||
Income From Continuing Operations Margin % | 16.17 | 45.42 | 13.42 | 18.37 | 23.08 | |||||
Net Income Margin % | 16.18 | 45.43 | 13.42 | 31.83 | 23.09 | |||||
Net Avail. For Common Margin % | 16.18 | 45.43 | 13.42 | 18.36 | 23.09 | |||||
Normalized Net Income Margin | 14.93 | 32.16 | 14.66 | 16.32 | 18.91 | |||||
Levered Free Cash Flow Margin | 26.59 | 24.81 | 18.69 | 26 | 23.27 | |||||
Unlevered Free Cash Flow Margin | 27.68 | 25.77 | 19.7 | 27.15 | 24.49 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.4 | 0.41 | 0.42 | 0.43 | 0.51 | |||||
Fixed Assets Turnover | 3.6 | 3.91 | 4.1 | 4.04 | 4.75 | |||||
Receivables Turnover (Average Receivables) | 5.89 | 6.36 | 6.29 | 5.99 | 6.93 | |||||
Inventory Turnover (Average Inventory) | 2.2 | 2.24 | 2.18 | 1.84 | 2.2 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.9 | 1.51 | 1.29 | 1.16 | 1.04 | |||||
Quick Ratio | 0.65 | 1.25 | 1 | 0.88 | 0.79 | |||||
Operating Cash Flow to Current Liabilities | 0.41 | 0.5 | 0.5 | 0.55 | 0.61 | |||||
Days Sales Outstanding (Average Receivables) | 62.12 | 57.35 | 58.03 | 60.94 | 52.84 | |||||
Days Outstanding Inventory (Average Inventory) | 166.64 | 163.13 | 167.46 | 198.72 | 166.16 | |||||
Average Days Payable Outstanding | 127.43 | 133.56 | 125.22 | 170.86 | 137.67 | |||||
Cash Conversion Cycle (Average Days) | 101.34 | 86.91 | 100.27 | 88.79 | 81.33 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 67.15 | 45.84 | 47.06 | 56.55 | 71.16 | |||||
Total Debt / Total Capital | 40.17 | 31.43 | 32 | 36.12 | 41.58 | |||||
LT Debt/Equity | 49.37 | 36.16 | 36.66 | 42.85 | 51.97 | |||||
Long-Term Debt / Total Capital | 29.54 | 24.79 | 24.93 | 27.37 | 30.37 | |||||
Total Liabilities / Total Assets | 57.09 | 48.54 | 49.41 | 53.22 | 56.84 | |||||
EBIT / Interest Expense | 14.02 | 15.81 | 15.36 | 14.79 | 16.22 | |||||
EBITDA / Interest Expense | 20.41 | 22.51 | 21.87 | 20.79 | 20.79 | |||||
(EBITDA - Capex) / Interest Expense | 18.94 | 20.81 | 20.44 | 19.55 | 19.44 | |||||
Total Debt / EBITDA | 2.15 | 1.7 | 1.53 | 1.49 | 1.5 | |||||
Net Debt / EBITDA | 1.5 | 0.16 | 0.5 | 0.7 | 0.86 | |||||
Total Debt / (EBITDA - Capex) | 2.31 | 1.84 | 1.63 | 1.58 | 1.61 | |||||
Net Debt / (EBITDA - Capex) | 1.62 | 0.17 | 0.54 | 0.74 | 0.92 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 2.51 | 5.97 | -1.98 | 7.36 | 10.85 | |||||
Gross Profit, 1 Yr. Growth % | 2.16 | 5.48 | -1.86 | 7.7 | 12.32 | |||||
EBITDA, 1 Yr. Growth % | 10.17 | 5.71 | 0.38 | 9.93 | 17.95 | |||||
EBITA, 1 Yr. Growth % | 9.79 | 6.89 | 0.68 | 10.91 | 19.12 | |||||
EBIT, 1 Yr. Growth % | 6.74 | 5.23 | 0.27 | 12.78 | 29.09 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 12.93 | 197.58 | -71.04 | 41.71 | 39.28 | |||||
Net Income, 1 Yr. Growth % | -31.2 | 197.58 | -71.05 | 113.52 | -19.59 | |||||
Normalized Net Income, 1 Yr. Growth % | 5.73 | 128.24 | -55.51 | 15.19 | 28.45 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 14.29 | 201.99 | -70.18 | 48.55 | 43.17 | |||||
Accounts Receivable, 1 Yr. Growth % | -1.01 | -2.58 | 0.76 | -11.89 | 4.45 | |||||
Inventory, 1 Yr. Growth % | 19.21 | -6.52 | 7.64 | -17.59 | -3.21 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 1.4 | -5.98 | -6.95 | -10.42 | -0.47 | |||||
Total Assets, 1 Yr. Growth % | 11.56 | 3.14 | -10.88 | -14.91 | 2.3 | |||||
Tangible Book Value, 1 Yr. Growth % | -198.62 | -270.18 | -69.95 | -36.98 | 114.61 | |||||
Common Equity, 1 Yr. Growth % | 2.03 | 19.54 | -12.29 | -21.36 | -5.62 | |||||
Cash From Operations, 1 Yr. Growth % | 0.18 | 10.41 | -5.54 | 1.56 | 21.86 | |||||
Capital Expenditures, 1 Yr. Growth % | -7.54 | 8.08 | -13.06 | 15.72 | 28.87 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -3.16 | 2.26 | -26.16 | 41.76 | -0.78 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -2.96 | 1.89 | -25.07 | 39.84 | -0 | |||||
Dividend Per Share, 1 Yr. Growth % | 8.97 | -0.02 | 1.77 | 13.24 | -1.44 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 4.04 | 4.22 | 1.92 | 3.01 | 9.09 | |||||
Gross Profit, 2 Yr. CAGR % | 6.01 | 4.55 | 2.79 | 3.11 | 10.47 | |||||
EBITDA, 2 Yr. CAGR % | 10.97 | 16.27 | 9.81 | 5.86 | 21.75 | |||||
EBITA, 2 Yr. CAGR % | 12.56 | 18.45 | 11.22 | 6.53 | 23.47 | |||||
EBIT, 2 Yr. CAGR % | 16.86 | 18.8 | 12.55 | 7.38 | 33.09 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -20.59 | 83.32 | -7.17 | -38.82 | 40.49 | |||||
Net Income, 2 Yr. CAGR % | -20 | 43.09 | -7.18 | -21.37 | 31.03 | |||||
Normalized Net Income, 2 Yr. CAGR % | -9.68 | 74.52 | 10.91 | -30.86 | 35.05 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -19.71 | 85.78 | -5.1 | -36.41 | 45.84 | |||||
Accounts Receivable, 2 Yr. CAGR % | -2.97 | -1.8 | -0.92 | -5.78 | -4.07 | |||||
Inventory, 2 Yr. CAGR % | 1.25 | 5.56 | 0.31 | -5.82 | -10.69 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -5.76 | -2.36 | -6.46 | -8.7 | -5.58 | |||||
Total Assets, 2 Yr. CAGR % | -4.75 | 5.52 | -4.13 | -12.92 | -6.7 | |||||
Tangible Book Value, 2 Yr. CAGR % | -47.04 | 29.55 | -28.49 | -56.48 | 64.49 | |||||
Common Equity, 2 Yr. CAGR % | -15.15 | 10.43 | 2.4 | -16.95 | -13.85 | |||||
Cash From Operations, 2 Yr. CAGR % | -2.2 | 5.17 | 2.12 | -2.05 | 11.25 | |||||
Capital Expenditures, 2 Yr. CAGR % | 0.83 | -0.04 | -3.07 | -0.28 | 22.12 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 14.29 | 4.37 | -8.45 | 1.51 | 28.32 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 13.4 | 4.09 | -8.14 | 1.62 | 27.34 | |||||
Dividend Per Share, 2 Yr. CAGR % | 9.42 | 4.24 | 1.03 | 7.35 | 5.64 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 4.76 | 4.68 | 2.11 | -2.21 | 5.56 | |||||
Gross Profit, 3 Yr. CAGR % | 5.78 | 5.83 | 2.37 | -0.13 | 6.09 | |||||
EBITDA, 3 Yr. CAGR % | 10.59 | 8.26 | 10.71 | 5.47 | 9.74 | |||||
EBITA, 3 Yr. CAGR % | 10.6 | 10.64 | 12.2 | 6.84 | 10.58 | |||||
EBIT, 3 Yr. CAGR % | 10.86 | 12.85 | 12.27 | 7.59 | 14.18 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 2.48 | 23.34 | -0.9 | 2.03 | -19.52 | |||||
Net Income, 3 Yr. CAGR % | 1.57 | 23.96 | -15.99 | 22.53 | -20.78 | |||||
Normalized Net Income, 3 Yr. CAGR % | 8.45 | 23.02 | 10.81 | 7.24 | -15.01 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 3.55 | 24.87 | 0.96 | 5.22 | -16.66 | |||||
Accounts Receivable, 3 Yr. CAGR % | -1.51 | -2.84 | -0.95 | -4.72 | -2.48 | |||||
Inventory, 3 Yr. CAGR % | 1.27 | -1.41 | 6.25 | -6.05 | -4.96 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -5.4 | -5.83 | -3.91 | -7.8 | -6.04 | |||||
Total Assets, 3 Yr. CAGR % | -0.26 | -3.26 | -0.26 | -7.86 | -8.11 | |||||
Tangible Book Value, 3 Yr. CAGR % | -32.24 | -21.85 | -20.4 | -31.44 | -6.66 | |||||
Common Equity, 3 Yr. CAGR % | -8.62 | -4.88 | 2.27 | -6.23 | -13.33 | |||||
Cash From Operations, 3 Yr. CAGR % | 2.65 | 1.83 | 1.47 | 1.94 | 5.34 | |||||
Capital Expenditures, 3 Yr. CAGR % | -1.27 | 3.19 | -4.58 | -5.97 | 8.62 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 15.25 | 8.9 | -7 | 1.63 | 0.74 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 14.77 | 8.25 | -6.71 | 1.54 | 1.08 | |||||
Dividend Per Share, 3 Yr. CAGR % | 4.96 | 6.08 | 3.51 | 4.94 | 4.34 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -0.19 | 1.38 | 3.61 | 0.24 | 1.22 | |||||
Gross Profit, 5 Yr. CAGR % | 1.48 | 3.16 | 4.15 | 1.86 | 2.58 | |||||
EBITDA, 5 Yr. CAGR % | 4.15 | 4.43 | 6.94 | 4.38 | 9.26 | |||||
EBITA, 5 Yr. CAGR % | 4.21 | 5.26 | 7.8 | 6.09 | 10.65 | |||||
EBIT, 5 Yr. CAGR % | 6.3 | 7.13 | 7.53 | 7.21 | 12.43 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 2.81 | 29.1 | -1.49 | -7.71 | 10.81 | |||||
Net Income, 5 Yr. CAGR % | -14.61 | 29.05 | -2.02 | 3.32 | 0.35 | |||||
Normalized Net Income, 5 Yr. CAGR % | 7.78 | 24.74 | 5.4 | -3.57 | 11.87 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 4.1 | 30.58 | 0 | -5.57 | 13.77 | |||||
Accounts Receivable, 5 Yr. CAGR % | 0.09 | -0.49 | -1.27 | -4.02 | -2.21 | |||||
Inventory, 5 Yr. CAGR % | 2.75 | 1.28 | 0.88 | -3.2 | -0.88 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -2.7 | -3.47 | -5.83 | -6.99 | -4.58 | |||||
Total Assets, 5 Yr. CAGR % | 0.08 | 0.26 | -2.47 | -7.24 | -2.89 | |||||
Tangible Book Value, 5 Yr. CAGR % | -18.29 | -10.98 | -30.76 | -38.17 | 6.42 | |||||
Common Equity, 5 Yr. CAGR % | -5.98 | -2 | -4.36 | -9.9 | -4.51 | |||||
Cash From Operations, 5 Yr. CAGR % | 2.79 | 5.6 | 2.44 | 0.26 | 5.28 | |||||
Capital Expenditures, 5 Yr. CAGR % | -11.64 | -5.84 | -2 | -3.31 | -0.19 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 0.88 | 11.08 | 2.25 | 3.62 | -0.01 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 1.05 | 10.69 | 2.25 | 3.36 | 0.15 | |||||
Dividend Per Share, 5 Yr. CAGR % | 4.74 | 4.5 | 3.31 | 6.65 | 4.36 |
- Stock Market
- Equities
- NOVN Stock
- Financials Novartis AG
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















